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Background: Head and neck cancer (HNC) is a highly invasive cancer. Aurora-A has been reported for a number of
malignancies. However, the identity of downstream effectors responsible for its aggressive phenotype in HNC
remains underinvestigated.
Methods: The mRNA and protein expression levels of Aurora-A and FLJ10540 were assessed in HNC specimens and
cell lines using RT-qPCR, western blot, Oncomine, and microarray database analysis. The downstream molecular
mechanisms of Aurora-A were confirmed by RT-qPCR, western blot, luciferase reporter, confocal microscopy analyses,
immunoprecipitation, colony formation, cell viability, and xenograft model. Cellular functions in response to
Aurora-A-modulated downstream targets such as FLJ10540 and MMPs were examined in vitro and in vivo, including cell
growth, motility and chemosensitivity. Aurora-A/FLJ10540/MMPs expression was determined in cancer and adjacent
normal tissues from HNC patients by immunohistochemistry approach.
Results: In the current study, Aurora-A exhibited similar gene expression profiles with FLJ10540 by using accessibly
public microarray and Oncomine database analysis, raising the possibility that these molecules might coordinately
participate in cancer progression and metastasis of HNC. These two molecules connection were also examined in cell
lines and tissues of HNC. Aurora-A overexpression could not only bind to the promoter of FLJ10540 to induce
FLJ10540 expression, but also increase both mRNA and protein levels of MMP-7 and MMP-10 in HNC cells. Conversely,
depletion of Aurora-A expression by using siRNA or Aurora-A kinase inhibitor, MLN8237, suppressed FLJ10540, MMP-7
and MMP-10 mRNA and protein expressions in vitro and in vivo. In addition, the FLJ10540-PI3K complex was destroyed
by inhibition the Aurora-A kinase activity. Forced overexpression of FLJ10540 in Aurora-A-depleted or in
MLN8237-treated HNC cells attenuated the effect on cytotoxicity to cisplatin. Elevated Aurora-A expression in HNC cells
led to the characteristics of more aggressive malignancy, including enhanced chemoresistance and increased the
abilities of proliferation, migration and invasion, which was required for FLJ10540/MMP-7 or FLJ10540/MMP-10
expressions. Finally, immunohistochemical analysis of human HNC specimens showed a significant positively
correlation among Aurora-A, FLJ10540, MMP-7 and MMP-10 expressions.
Conclusion: Together, our findings define a novel mechanism by which Aurora-A promotes cell malignancy, with
potential implications for understanding the clinical action of Aurora-A.
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Head and neck cancer (HNC) is the sixth most common
cancer worldwide, the incidence of HNC is estimated at
560,000 new cases and 300,000 deaths annually [1]. Ap-
proximately 90% of HNC arises in the mucosa of the
oral cavity, oropharynx, larynx and hypopharynx. Ac-
cording to a histopathological perspective, more than
90% of HNC are squamous cell carcinomas [2]. Both en-
vironmental factors and genetic inheritance can give rise
to the development of HNC. Tobacco, alcohol consump-
tion and areca nut are major risk factors for the develop-
ment of this disease. Patients with early stage can be
cured by therapy; however, two-third of HNC patients
with advanced disease at time of diagnosis, due to HNC
has a high potential for local recurrent, invasion and
lymph node metastasis [3]. The most common treatment
modalities for HNC include surgery, radiation, and
chemotherapy, often in combination. Despite new treat-
ment options for HNC patients, the 5-year mortality rate
has not improved over the past 3 decades. Therefore, in-
vestigations specifically aimed at further understanding
the molecular basis involving in HNC carcinogenesis
can facilitate the integration of diagnosis and therapy for
HNC in the future.
Aurora-A, also designated as STK15/STK6, is a serine/
threonine kinase that plays a crucial role in mitosis and
spindle assembly during various stage of mitosis. Aberrant
Aurora-A amplification and/ or overexpression has been
reported in human malignancies, such as colon, neuro-
blastoma, breast, oral, NPC, pancreas, ovary, lung, esopha-
gus cancers [4-13]. Increased Aurora-A expression may
cause genomic instability, tumorigenesis, metastasis and
chemoresistance, correlating with its pro-survival function
in cancer cells [14]. Accumulated reports indicate that
evaluated Aurora-A expression is not only correlated with
advanced stage of tumors, but also associated with a
poorer outcome of patients. Recent studies have shown
that oncogenic signaling pathways, such as GSK-3β, c-
Myc, AKT, β-catenin, p53 and NF-κb involved in
Aurora-A function in cancers [15]. Based on these results,
Aurora-A plays a key converging point of a complex net-
work of oncogenic signaling pathway. However, the role of
Aurora-A in the signaling transduction pathway involved
in tumorigenesis of HNC has not been fully clarified.
FLJ10540, a protein of 464 amino acids, has been
mapped to the 10q23 chromosomal region. This protein
contains three coiled-coil domains, a peroxisomal target-
ing signal 2, a nuclear export signal, and structure main-
tenance of chromosome (SMC) domain. Frequent
overexpression of FLJ10540 has been reported in HCC,
lung, OSCC, and NPC [16-20]. FLJ10540 is a mitotic
phosphoprotein and has been reported to be an essential
regulator of cytokinesis controlled by Cdk1 and ERK2
[21]. Deregulated expression of FLJ10540 may causecytokinesis defects, genetic instability and oncogenic
transformation [22]. Highly FLJ10540 expression pro-
motes progrowth signaling pathways resulting in cancer
cell proliferation, metastasis and poor patient prognosis
in human cancers [16] [17,20]. Therefore, the oncogenic
potential and essential roles in cell cycle of FLJ10540
make it an intriguing target for anticancer therapeutic
intervention.
In the present study, we demonstrate for the first time
that Aurora-A induced FLJ10540 expression not only in-
fluences FLJ10540/PI3K complex, but also regulates
MMP-7 and MMP-10 activations, thereby leading to the
proliferation, metastasis of HNC cells and their resist-
ance to cisplatin treatment in HNC.
Materials and methods
Reagents
MLN8237 and GM6001 were purchased from Selleck
Chemicals. Cisplatin was purchased from Sigma-Aldrich.
All chemicals were dissolved in dimethyl sulfoxide
(DMSO) for in vitro studies.
Human HNC tissue samples and IHC
Commercially purchased tissue microarrays (TMAs) in-
cluded 80 samples of 11 cases in early stage, 59 cases in
advanced stage and 10 normal tissue (US Biomax, Inc.,
Rockville, MD, USA; catalog number HN802). This
study was approved by the Medical Ethics and Human
Clinical Trial Committee at Chang Gung Memorial Hos-
pital. Tissues were fixed with 10% buffered formalin em-
bedded in paraffin and decalcified in 10% EDTA
solution. Representative blocks of the formalin-fixed,
paraffin-embedded tissues were cut to 4 mm and depar-
affinized with xylene and rehydrated in a series of etha-
nol washes (100, 90, 80, and 70%). Slides were washed
with phosphate-buffered saline (PBS) and treated with
3% H2O2 for 30 minutes to block endogenous peroxid-
ase activity. Next, the sections were microwaved in
10 mM citrate buffer, pH 6.0, to unmask the epitopes.
After antigen retrieval, the sections were incubated with
diluted anti-Aurora-A, anti-FLJ10540, anti-MMP-7 and
anti-MMP-10 antibodies for 1 h followed by washing
with PBS. Horseradish peroxidase/Fab polymer conju-
gate (PicTure™-Plus kit; Zymed, South San Francisco,
CA, USA) was then applied to the sections for 30 min
followed by washing with PBS. Finally, the sections were
incubated with diaminobenzidine for 5 min to develop
the signals. A negative control was run simultaneously
by omitting the primary antibody. The reactivity level of
the immunostained tissues was evaluated independently
by two pathologists who were blind to the subjects’ clin-
ical information. Between 15 and 20 high-power fields
were viewed. Criteria were developed for quantitating
the immunoreactivities of the Aurora-A, FLJ10540,
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tumor sections using a score range of 0 to +3, where 0
indicated no positive cell staining, +1 less than 10% posi-
tive cell staining, +2 10-30% positive cell staining, and
+3 more than 30% positive cell staining. Similarly, the
stain intensity was graded as +0, +1, +2, or +3 as previ-
ously described [23].
Cell culture, transient transfection, the establishment of
stable clones, and luciferase assay
FaDu and SAS cell lines were obtained from the American
Type Culture Collection. All cell culture-related reagents
were purchased from Gibco-BRL (Grand Island, NY,
USA). FaDu and SCC4 cells were grown in DMEM
containing 10% FBS and 100 U/ml penicillin and
streptomycin (Gibco-BRL) Flag-vector (pcDNA3.1),
Flag-Aurora-A and Flag-FLJ10540 were transiently trans-
fected into cancer cells using Lipofectamine (Invitrogen)
according to the manufacturer’s instructions. FaDu cells
mixed-stably expressing Aurora-A or FLJ10540 were se-
lected with 400 μg/ml G418 (Calbiochem Novabiochem,
San Diego, CA, USA) for two weeks. The cell were then
harvested and analyzed for exogenous Aurora-A and
FLJ10540 expressions by Western blotting. 5′-upstream
fragments of FLJ10540 gene (−1 ~ −2000) was amplified
from human genomic DNA and verified by sequencing.
The PCR fragments were cloned into firefly luciferase re-
porter vector pGL3-Basic (Promega) NheI and HindIII
sites which were designed into the forward and the reverse
primers, respectively. For co-transfection experiments,
FaDu cells were co-transfected with 100 ng firefly lucifer-
ase reporter plasmids (pGL3-Basic or pGL3-FLJ10540),
and 10 ng of pRL-TK Renilla luciferase internal control
plasmid. After 24 h, the luciferase activity was measured
using Dual Glo™ Luciferase Assay System (Promega). Two
double-stranded synthetic RNA oligomers (5′-GCAGAG
AACUGCUACUUAUtt-3′ deduced from human Aurora-
A; and 5′-GGACTTTTAGCAAAGATCTtt-3′ deduced
from human FLJ10540; Ambion; Taipei, Taiwan) deduced
from human Aurora-A, and one negative control siRNA
(#4611G; Ambion) were used in the siRNA experiments.
Immunoblot analysis
For tissue protein extraction, frozen samples were homog-
enized in RIPA lysis buffer (50 mM Tris–HCl, pH 7.5,
150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, and
0.1% SDS). The protein concentration in each sample was
estimated by Bio-Rad Protein Assay (Bio-Rad, Hercules,
CA, USA). Immunoblotting was performed according to
standard procedures. Antibodies used in this study in-
clude Aurora-A (monoclonal; Epitomics, Burlingame, CA,
USA), MMP-7 (monoclonal; Millipore), MMP-10 (mono-
clonal; Millipore), FLJ10540 (generated by us) and β-actin
(monoclonal; Santa Cruz Biotechnology, Santa Cruz, CA,USA). The first antibodies were detected by incubation
with secondary antibodies conjugated to HRP (Bio/Can
Scientific, Mississauga, ON, Canada) and developed using
Western Lighting Reagent. The proteins were explored by
X-ray films. The protein expression levels were quantified
by ImageJ Software and represented as the densitometric
ratio of the targeted protein to GAPDH or β-actin.
Indirect immunofluorescence analysis and microscopy
The indirect immunofluorescence staining on the HNC
cells treated with MLN8237 or Aurora-A/siFLJ10540 was
performed with anti-FLJ10540, at RT for 2 h. The sections
were then washed three times with PBST and incubated
with DAPI and goat-anti-rabbit-FITC (Jackson, Immu-
noResearch) at RT for 1 h. After washing with PBST, the
sections were mounted with GEL/Mount (biomeda corp,
Foster, CA). The fluorescence images on the slips were ex-
amined using a confocal microscope (Olympus FV10i).
RNA extraction, semi-quantitative RT-PCR, and quantitative
RT-PCR
Samples were frozen in liquid nitrogen and stored at −80°C
prior to RNA extraction. The cells were homogenized
using a Mixer Mill Homogenizer (Qiagen, Crawley, West
Sussex, UK). Total RNA was prepared from the frozen tis-
sue samples using an RNeasy Mini Kit (Qiagen) according
to the manufacturer’s instructions. The RNA (2 μg) was
then reverse transcribed into cDNA using SuperScript II
Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA).
For Q-RT-PCR, Aurora-A, FLJ10540 and MMPs Taq-Man
probe (ABI) were used to perform the study. Data were
represented as mean ± s.d. To analyze the distribution
of control and experimental groups, we performed the
Wilcoxon signed rank test between two groups for statis-
tical analysis. A P-value of less than 0.05 was significant.
GAPDH (ABI) was used as an internal control for com-
parison and normalization the data. Assays were per-
formed in triplicate using Applied Biosystems Model 7700
instruments.
Migration, and invasion assays
Migration and invasion assays were conducted with
FaDu-vehicle, FaDu/Aurora-A/negative, FaDu/Aurora-
A/siFLJ10540, FaDu/Aurora-A/DMSO, and FaDu/Aur-
ora-A/GM6001 cells using 24-well Transwell chambers
(8-μm pore size polycarbonate membrane; Costar, Corning,
NY). For the migration (5 x 103) and invasion (1 x 104)
assays, cells were suspended in 400 μl of DMEM con-
taining 10% FBS, then seeded into the upper chamber;
600 μl of DMEM containing 10% FBS were added to
the outside of the chamber. After being cultured at 37°C
under 5% CO2/95% air for 24 h, the cells on the upper
surface of the membrane were removed with a cotton-
tipped applicator and the migratory cells on the lower
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with Giemsa (Sigma, USA). Cell migration was evaluated
by counting the number of FaDu-vehicle, FaDu/Aurora-
A/negative, FaDu/Aurora-A/siFLJ10540, FaDu/Aurora-A/
DMSO, and FaDu/Aurora-A/GM6001 cells that had
migrated by 200× phase-contrast microscopy on three in-
dependent membranes, then normalized against the ve-
hicle cells to determine the relative ratio. For the invasion
assays, 80 μg/ml of Matrigel (BD Biosciences) were added
to the upper surface of the membrane and allowed to gel
at 37°C overnight. A total cells (1×105) in 400 μl of
DMEM containing 10% FBS were seeded into the upper
chamber, while 600 μl of DMEM containing 10% FBS
were added to the outside of the chamber. The rest of the
protocol was the same as that for the migration assays.
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed according to the protocol
from Millipore (EZ–Magna ChIP G Chromatin Immu-
noprecipitation Kit, Millipore). FaDu cells transfected
with vehicle control and HA fused Aurora-A according
to the manufacturer’s instruction that was describe
above. Chromatin was precipitated using anti-HA anti-
body and protein A agarose at 4°C overnight and im-
mune complexes were collected by centrifugation.
Normal human IgG was used as a control. Cross-links
were then reversed at 65°C overnight. The purified DNA
was amplified by PCR using FLJ10540 promoter primers
pre-denaturation for 3 min at 94°C, denaturation at 94°C
for 20 sec., annealing at 47°Cfor 30 sec., and extension
at 72°C for 30 sec. for a total of 30 cycles).
Measurement of MMP-7 and MMP-10 protein
The amount of MMP-7 and MMP-10 proteins in the
conditioned media was determined using the human
MMP-7 and MMP-10 Quantikine ELISA kits (R&D Sys-
tems, Minneapolis, MN, USA) according to the manu-
facturer’s instructions. The amounts of MMP-7 and
MMP-10 were calculated from a standard curve.
Cell viability assay and colony formation assay
Viability of sub-confluent cells was analyzed by 3-(4,5-
dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) reduction assay. FaDu/vehicle + negative control,
FaDu/vehicle + siFLJ10540, FaDu/Aurora-A + negative con-
trol, FaDu/Aurora-A + siFLJ10540, SAS/negative control,
SAS/vehicle + negative control, SAS/FLJ10540 + negative
control, SAS/siAurora-A, SAS/vehicle + siAurora-A, and
SAS/FLJ10540 + siAurora-A cells were seeded at 5 × 103
cells/well in 96-well plates. Next day, cells were treated
with MLN8237 (0.025 nM) or cisplatin (15 μM) or in
combination for 48 h. After that, MTT solution was added
to each well. The plates were stored at 37°C for 4 hour,
and then 100 μL DMSO buffer was added and incubatedin the dark for 10 min. Absorbance was measured on a
microplate reader at 540 nm. The OD values were nor-
malized with the value of control group. For colony for-
mation assay, cells were seeded in 60-mm dishes at a
density of 5 × 103 cells. Next day, cells were treated with
MLN8237 (0.025 nM) and cisplatin (15 μM) or GM6001
(3 μM) for 48 h. After washing with PBS, the cells were in-
cubated in drug-free complete medium for 15 days. Sub-
sequently, cell colonies were counted after staining with
0.01% crystal violet.
Animal experiments and immunohistochemistry
Parental SAS, SAS/negative control and SAS/siFLJ10540
cells were harvested, washed in PBS, and suspended in a
mixture of PBS and Matrigel (BD Biosciences, San Jose,
CA, USA). 1 × 106 cells were injected into the flanks of
female nude mice. All animal experiments were carried
out in accordance with protocols approved by the Ani-
mal Use and Management Committee of Kaohsiung
Chang-Gung Memorial Hospital. After tumor growth
reached 100 mm3, mice were assigned to receive
MLN8237 or DMSO by oral gavage for 14 days. Mice
were monitored daily and tumor volumes and body
weights were measured twice weekly. At the completion
of the study, tumors were excised, formalin-fixed and
paraffin-embedded for immunohistochemical analysis.
Statistical analysis
All in vitro experiments were performed in triplicates.
ANOVA analysis was used to evaluate statistical difference
between groups. The correlation between two parameters
was determined by the Spearman correlation. The P value
of 0.05 or less was considered statistically significant.
Results
FLJ10540 and Aurora-A are abnormally co-expressed in
HNC tumor tissues and cell lines
Previous reports have indicated that either Aurora-A or
FLJ10540 involves in multiple signaling pathways to
promote cancer progression [12,13,15,17,24,25]. Intersec-
tion of these pathways elicited by either Aurora-A or
FLJ10540, we found that these two molecules have shared
common signal pathways for subsistence of tumor cells.
First, to determine the clinical significances of both
Aurora-A and FLJ10540 in patients with HNC, we per-
formed data mining and analyzed both Aurora-A and
FLJ10540 expressions from the publicly available Onco-
mine database. The finding for Aurora-A and FLJ10540
gene expressions based on 13 databases exhibited six with
a significant p-value (p < 0.001) and gene ranks in the top
10% among all differentially expressed genes. In these six
databases, Aurora-A and FLJ10540 were up-regulated in
tumor tissues of HNC compared with normal tissues
(Figure 1A). Next, from cDNA microarray analysis using
Figure 1 (See legend on next page.)
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Figure 1 Clinical and cellular significances of FLJ10540 and Aurora-A in HNC. (A) Oncomine data mining analysis of Aurora-A and FLJ10540 mRNA
levels in six different datasets between normal tissues versus head and neck carcinomas. (B) The correlation between the relative expression levels
of FLJ10540 and Aurora-A in microarray database of HNC. (C and D) The mRNA and protein expression levels of FLJ10540 and Aurora-A in HNC
cells were analyzed by Q-RT-PCR and Western blotting. GAPDH and β-actin were used as internal control. (E) Western blotting analysis of FLJ10540
and Aurora-A expressions were determined in paired HNC patients. Total proteins were extracted from adjacent non-cancerous and tumor tissues and
probed with polyclonal antibodies against Aurora-A and FLJ10540. β-actin was used as a control. Images were quantified with ImageJ software.
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FLJ10540 was highly positively correlated with the mRNA
expression level of Aurora-A in specimens of HNC pa-
tients (r = 0.72, p < 0.001) (Figure 1B). These results raise
the possibility that Aurora-A and FLJ10540 have function-
ally linked in human cancers. To this end, we first exam-
ined the expression levels of Aurora-A and FLJ10540 in
HNC cell lines. It was indicated that the mRNA and pro-
tein expression levels of Aurora-A were paralleled the
levels of increased FLJ10540 mRNA and protein as deter-
mined by Q-RT-PCR and Western blotting (Figure 1C
and D). In addition, we further investigated Aurora-A and
FLJ10540 protein expression profiles in paired specimens
of HNC. The result demonstrates that both Aurora-A and
FLJ10540 expressions are paralleled elevated in HNC
specimens (Figure 1E), suggesting a potential functional
association between Aurora-A and FLJ10540 in HNC.
FLJ10540 expression is modulated by Aurora-A in HNC
cells
To further explore the correlation between Aurora-A and
FLJ10540 in HNC cells, we first inspected whether
Aurora-A expression could be modulated by FLJ10540.
FaDu cells were chosen for ectopic expressions of Aurora-
A and FLJ10540 because of the low endogenous Aurora-A
and FLJ10540 levels, and SAS cells were selected to gener-
ate the Aurora-A- and FLJ10540-knockdown systems
owing to the higher endogenous Aurora-A and FLJ10540
expression levels. The data showed that both endogenous
mRNA and protein expressions of Aurora-A were not al-
tered in SAS and FaDu cells with FLJ10540-gain or -loss
of functions, compared to the vehicle or negative control
(Figure 2A and B) as detected by Q-RT-PCR and Western
blotting. Next, we established overexpression and deple-
tion of Aurora-A-HNC cell lines to determine the effect
of FLJ10540 expression. As shown in the Figure 2C, com-
pared with the vehicle control, the mRNA and protein ex-
pression levels of FLJ10540 were dramatically increased in
overexpressed-Aurora-A-FaDu cells. Conversely, Aurora-
A depletion led to reduction in FLJ10540 expression both
on mRNA and protein levels in SAS cells (Figure 2D). To
investigate whether FLJ10540 was transcriptionally in-
duced by Aurora-A, the human promoter sequences of
FLJ10540 fused luciferase reporter-based plasmid was
generated and assessed the promoter activity of FLJ10540
in FaDu cells by Aurora-A modulation. Expressing Flag-Aurora-A or Flag alone was co-transfected with reporter
plasmids respectively and luciferase activity determined
after normalizing for transfection efficiency. Remarkably,
Flag-Aurora-A overexpressing had 2- to 4-fold increases
in FLJ10540 promoter activity compared with vehicle
alone (Figure 2E). In contrast, the promoter activity of
FLJ10540 was decreased while endogenous Aurora-A
was knock-downed in SAS cells (Figure 2F). To confirm
the binding of Aurora-A to the FLJ10540 promoter,
chromatin-immunoprecipitation assay was performed.
The results indicated that using α-Flag antibodies were
able to specifically immunoprecipitate FLJ10540 promoter
in cells transfected with Flag-Aurora-A; however, the con-
trol IgG isotype did not exhibit specific immunoprecipita-
tion. Conversely, the FLJ10540 promoter region was not
able to be precipitated in SAS cells transfected with
Aurora-A siRNA (Additional file 1: Figure S1). Taken
together, the earlier findings illustrate that in HNC
cells, FLJ10540 is one of the downstream targets of
Aurora-A.
MLN8237 inhibits the expression of FLJ10540 and
disrupts the FLJ10540-PI3K association in HNC cells
MLN8237, an ATP-competitive and reversible inhibitor
has been shown to inhibit Aurora-A activity in advanced
malignancies [7,26]. To further confirm the positive cor-
relation between Aurora-A activity and FLJ10540, we ex-
amined FLJ10540 expression by Q-RT-PCR and Western
blotting under the condition of Aurora-A inhibition by
MLN8237 treatment in SAS cell lines. As shown in Fig-
ure 3A and B, MLN8237 significantly reduced FLJ10540
mRNA and protein expressions in a concentration-
dependent manner. To determine whether Aurora-A ac-
tivity induction of FLJ10540 is regulated at the level of
transcription, FLJ10540 reporter-based plasmids were
transfected into FaDu cells under treatment of MLN8237
in a dose-dependent manner. As expected, the luciferase
activity of FLJ10540 was suppressed upon MLN8237 treat-
ment in a dose-dependent manner (Figure 3C). Next, we
further investigated the protein expression of FLJ10540 in
unsynchronized SAS cells by indirect immunofluores-
cence. It was indicated that indeed, endogenous FLJ10540
protein expression was decreased in HNC cells treated
with MLN8237 (Figure 3D). Our previous data demon-
strated that FLJ10540 may act as a scaffold protein to
stabilize the PI3K complex in human cancer cells
Figure 2 (See legend on next page.)
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Figure 2 Aurora-A upregulates FLJ10540 in HNC. (A and B) Flag-tagged FLJ10540 stable clone of FaDu cells and siFLJ10540 transfectants of SAS
cells were established. The cell lysates were subjected to immunoblot analysis with anti-Flag and FLJ10540 antibodies. β-actin is as an internal
control. Aurora-A mRNA and protein expression levels in FLJ10540-overexpressing and vehicle cells were recognized by Western blotting and
Q-RT-PCR. (C and D) Flag-tagged Aurora-A stable clone of FaDu cells and siAurora-A transfectants of SAS cells were established. The endogenous
mRNA and protein of FLJ10540 were detected by Western blotting and Q-RT-PCR. (E and F) The luciferase assays were performed to detect promoter
activities of FLJ10540 in cotransfected with in a dose-dependent manner of Flag, Flag-Aurora-A, negative control or siAurora-A. The FLJ10540 luciferase
activity was normalized to Renilla activity. Data are representative of three independent experiments done in triplicates. Images were quantified with
ImageJ software. Statistical analysis: *p < 0.05, ***p < 0.001.
Figure 3 FLJ10540 expression and PI3K-FLJ10540 complex are restrained upon MLN8237 stimulation in HNC cells. (A and B) The mRNA and
protein expression levels of FLJ10540 were examined by Q-RT-PCR and Western blotting in SAS cells in MLN8237 dose-dependent manner. The
results were normalized against the expression level of GAPDH mRNA in each MLN8237-treated cell. Using the same panel, the total proteins were
probed with antibodies against phosphorylated-Aurora-A, Aurora-A, FLJ10540 and β-actin. β-actin was used as a control. Data are representative
of three independent experiments done in triplicate. (C) Luciferase assays were done to detect promoter activity of FLJ10540 in transfected FaDu
cells in the presence or absence of MLN8237. (D) Unsynchronized HNC cells were fixed, and immunostained with antibodies against endogenous
FLJ10540 or DAPI. Representative data are shown. (E) Co-immunoprecipitation of FLJ10540 and PI3K. Cells treated with or without MLN8237 and
antibody of p110-α used for immunoprecipitation and representative western blot detection of p85-α and FLJ10540 were shown. Statistical
analysis: *p < 0.05, **p < 0.01, ***p < 0.001.
Chen et al. Molecular Cancer  (2015) 14:83 Page 8 of 18
Chen et al. Molecular Cancer  (2015) 14:83 Page 9 of 18[16,18,24]. According to data described above, we inspired
that FLJ10540 associated with PI3K is required Aurora-A
activity. The data illustrated that the associated strength of
PI3K-FLJ10540 complex was depended on Aurora-A ac-
tivity (Figure 3E). These data suggest that the Aurora-A
activity is critical for FLJ10540 expression and PI3K-
FLJ10540 interaction in HNC cells.
FLJ10540 mediates the function of Aurora-A on maintenance
of malignant state in vitro and in vivo
To elucidate the role of FLJ10540 in Aurora-A-driven
carcinogenesis on behavior change of HNC cells, the cell
proliferation, migration and invasive assays were per-
formed. First, Aurora-A stable cells transfected with nega-
tive control or siFLJ10540 were established. The mRNA
and protein expression levels of FLJ10540 were dramatic
reduced while endogenous FLJ10540 was depleted by
FLJ10540-mediated siRNAs in steady expressed Aurora-
A-FaDu cells (Figure 4A and B). Using the same panel, we
observed that the abilities of cell growth, migration and
invasion were inhibited in FaDu-Aurora-A stable cells
transfected with FLJ10540 siRNA (Figure 4C and D). In
addition, steady expressed Aurora-A/siFLJ10540 stable
cells exhibited anti-tumor growth and metastasis in vivo
(Additional file 2: Figure S2). Previous study reports that
Aurora-A participates in centrosome amplification. To
determine the role of FLJ10540 in this process, we ana-
lyzed centrosome amplification by immunofluorescence
(gamma-tubulin) in overexpressed Aurora-A cells with
FLJ10540 siRNA. The data indicated that nearly 10% of
cells with abnormal centrosome amplification in overex-
pressed Aurora-A cells. However, the percentage of
centrosome abnormalities dropped to less than 1%
while conveyed to FLJ10540 depletion (Figure 4E, and
Additional file 3: Figure S3). Next, to determine whether
simultaneous inhibition of Aurora-A and FLJ10540 exhib-
ited anti-tumor effect in vivo, xenograft models were used.
SAS alone or transfected with negative control or
siFLJ10540 cells were injected subcutaneously into the
right flank of nude mice. Treatment with MLN8237/or
DMSO was initiated when mean tumor volume was ap-
proximately 100 mm3 for all groups. As shown in
Figure 4F, treatment with MLN8237 retarded tumor
growth over the duration of the treatments, compared
to DMSO group. Further, co-treatment with MLN8237
and siFLJ10540 resulted in significantly greater inhib-
ition of tumor growth than treatment with MLN8237
alone. The mice tolerated all of the treatments without
significant body weight difference was observed. In
addition, the immunohistochemical staining showed
that the expression of endogenous FLJ10540 was sig-
nificantly decreased in treatment of MLN8237. Taken
together, these results suggest that Aurora-A raises thedevelopment of HNC at least partly, through modulat-
ing FLJ10540 expression.
Overexpression of FLJ10540 overturns the sensitivity of
Aurora-A-depleted and Aurora-A-inactivated cells to
cisplatin treatment
A recent studies have shown that Aurora-A contributes to
the resistance to cisplatin in breast, pancreatic, esophageal
squamous cell carcinoma, Acute myeloid leukemia, me-
dulloblastoma, and ovarian cancer cells [7,27-29]. To gain
insight the biological function of both Aurora-A and
FLJ10540 on chemoresistance to cisplatin, we carried out
MTT assay for assessing cell viability in siAurora-A trans-
fected cells and siAurora-A/FLJ10540-overexpressed cells
under cisplatin treatment. As shown in Figure 5A, the
viability of siAurora-A cells was significantly more sen-
sitive to cisplatin than negative control group in a
concentration-dependent manner. Notably, in the pres-
ence of cisplatin, siAurora-A transfectants with FLJ10540
exhibited a lower sensitivity than siAurora-A transfectants
or negative control to the cytotoxic effects of cisplatin
(Figure 5A). In addition, the viability of siAurora-A cells
was significantly lower than that of siAurora-A with
FLJ10540-overexpressing cells after incubation with cis-
platin (15 μM) for 48 hour (Figure 5B), indicating that
increased FLJ10540 decreases the sensitivity of Aurora-
A-depleted cells to cisplatin. Next, we used NLM8206
to investigate the effects of cisplatin in FLJ10540-
overexpressing cells. As shown in Figure 5C, FLJ10540
transfectants incubated with MLN8206 (0.025nM) and
cisplatin (15 μM) for 48 hour were significantly less vi-
able than the same cells treated with cisplatin alone or
MLN8206 alone. In addition, an assay of in vitro colony
formation was used to confirm the result of MTT assay.
As expected, FLJ10540 transfectants treated with
MLN8237 and cisplatin in combination increased the
colony-formation ability than that the vehicle control
(Figure 5D). Together, these results demonstrate that the
function of FLJ10540 modulated by Aurora-A expression
or Aurora-A activity contributes to cisplatin resistance in
HNC cells.
Both MMP-7 and −10 expressions not only modulate by
Aurora-A but also participate in Aurora-A-elicited cell
motility in HNC cells
MMPs plays a crucial role in tumor invasion and metas-
tasis for decades [30], and many MMPs contribute to
HNC progression [31,32]. According to recent report,
MMP-1, −2, −3, −7, −9, −10, −12, −13 and −14 are
highly expressed in HNC and involved in HNC progres-
sion through invadopodia formation [30]. Here, we
assessed these MMPs mRNA expression levels in
Aurora-A depleted HNC cells. The results illustrated
that only MMP-7 and −10 were dramatic suppressed in
Figure 4 (See legend on next page.)
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Figure 4 Depleted FLJ10540 attenuates Aurora-A elicited malignant phenotype changes in vitro and in vivo. (A and B) The mRNA and protein
expression levels of FLJ10540 were determined by Q-RT-PCR and Western blotting in vehicle or overexpressing Aurora-A transfectants. The cell
lysates of FaDu/vehicle-negative control, FaDu/vehicle-siFLJ10540, FaDu/Aurora-A-negative control, or FaDu/Aurora-A-siFLJ10540 transfectants
were subjected to immunoblot analysis with anti-FLJ10540, and β-actin antibodies. Data are representative of three independent experiments
done in triplicates. (C and D) Using the same panels, the proliferation, migration, and invasion assays were also performed by MTT assay and
Transwell chambers. (E) Centrosome numbers were determined in Aurora-A stable cells transfected with negative control or siFLJ10540 in FaDu
cells by using gamma-tubulin antibody. (F) Antitumor activity of MLN8237 plus siFLJ10540 in a SAS xenograft model. Nude mice bearing subcutaneously
established SAS alone (n = 6), SAS/negative control (n = 6) or SAS/siFLJ10540 (n = 6) xenograft tumors and received the indicated treatments.
Tumor growth was monitored and was shown as mean volumes ± SD. The paraffin-embedded tumor tissues were subjected to immunostaining for
FLJ10540. Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001.
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compared to negative control (p < 0.05) (Figure 6A). Our
Western blotting results are consistent with the ob-
served mRNA expressions of MMP-7 and −10 in SAS
cells transfected with siRNA of Aurora-A (Figure 6B). In
contrast, ectopic expression of Aurora-A in FaDu cells
was not only significantly enhanced the endogenousFigure 5 Reinforced FLJ10540 expression resists the cytotoxicity to cisplati
control or SAS/siAurora-A cells co-transfected with vehicle or FLJ10540 wer
and their percentage viability was measured and compared to that of untr
cisplatin (15 μM) for 48 hour, and their viability was measured. Vehicle and
cisplatin (15 μM) and/or MLN8237 for 48 hour (C) or 15 days (D) and total cel
*p < 0.05, **p < 0.01, ***p < 0.001.mRNA and protein expressions of MMP-7 and −10
(Figure 6C, D and E), but also increased the matricellular-
MMP-7 and −10 levels in culture media by ELISA assay
(Additional file 4: Figure S4). In xenograft tumor
model, the MMP-7 and MMP-10 protein expressions
were diminished in MLN8237 treated group compared
to DMSO by immunohistochemical staining (Figure 6F).n in depletion and inactivation cells of Aurora-A. (A) SAS/negative
e incubated with increasing concentrations of cisplatin for 48 hour,
eated respective cells. (B) The cells were cultured in the presence of
FLJ10540 transfectants were cultured in the presence or absence of
l viability were assessed by MTT assay and soft agar. Statistical analysis:
Figure 6 (See legend on next page.)
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Figure 6 Aurora-A modulates MMP-7 and MMP-10 expression and secretion in HNC cells. The mRNA expression levels of MMP-1, −2, −3, −7, −9, −10,
−12, −13 and −14 (A) and protein expression profiles of MMP-7 and −10 (B) were examined by Q-RT-PCR and Western blotting in SAS/negative control
and SAS/siAurora-A transfectants. (C and D) The endogenous mRNA and protein expression levels of MMP-7, and −10 (C) were examined by Q-RT-PCR
and Western blotting in FaDu/vehicle and FaDu/Aurora-A transfectants. (E) Unsynchronized Aurora-A transfectants were fixed, and immunostained
with antibodies against endogenous MMP-7 and −10 or DAPI. Representative data are shown. (F) Using the Figure 4F xenograft model. The
paraffin-embedded tumor tissues were subjected to immunostainings for MMP-7 and MMP-10. (G) The migration and invasion assays were
performed by Transwell chambers in Aurora-A transfectants treated with GM6001 (3 μM). D: DMSO; G: GM6001. Statistical analysis: *p < 0.05,
**p < 0.01, ***p < 0.001.
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in Aurora-A-elicited cell motility, we used an MMP in-
hibitor, GM6001 to inhibit MMP-7 and MMP-10 ex-
pressions [33]. The data showed that the mRNA
expression profiles of MMP-7 and −10 were decreased
in Aurora-A transfectants under GM6001 treatment in
a dose-dependent manner (Additional file 5: Figure S5).
Additionally, using the same panel, Aurora-A-raised
the abilities of cell migration and invasion were also
dramatic suppressed (Figure 6G). Taken together,
Aurora-A gives rise to the cell migration and invasion
rely on both MMP-7 and −10 expressions in HNC cells.
Aurora-A-mediated transcriptions and functions of both
MMP-7 and −10 are dependent on FLJ10540 regulation
To test whether FLJ10540 contributes to the regulation
of MMP-7 and −10 expressions in HNC, we investigated
the effects of FLJ10540 on MMP-7 and −10 levels. As
expected, both MMP-7 and −10 mRNA were up-
regulated in FLJ10540-overexpressing transfectants by
Q-RT-PCR (Figure 7A). Furthermore, FLJ10540 was not
only enhanced the endogenous protein expression
levels of both MMP-7 and −10, but also increased
MMP-7 and −10 secretion in culture medium by West-
ern blotting and ELISA approaches (Figure 7B). On the
contrary, mRNA and protein expression profiles of
both MMP-7 and −10 were remarkably decreased while
FLJ10540 was depleted in HNC cell lines (Figure 7C
and D). Furthermore, FLJ10540-elicited the abilities of
cell migration and invasion were also dramatic suppressed
while cells treated with GM6001 (Additional file 6: Figure
S6). To investigate whether MMP-7 and −10 expression
induced by Aurora-A is required FLJ10540, the secretory
proteins of both MMP-7 and −10 were determined in
Aurora-A transfectants in the present or absence of
FLJ10540 siRNA. The data indicated that inhibition of
FLJ10540 blocked MMP-7 and −10 secretions in response
to Aurora-A modulation (Figure 7E). Ultimately, the
Aurora-A-raised cell motility, growth, and chemoresis-
tance were also dramatic suppressed while Aurora-A
stable cells transfected with siFLJ10540 following
GM6001 treatment, compared to Aurora-A/negative con-
trol/GM6001 (Additional file 7: Figure S7). Collectively,FLJ10540 is crucial for Aurora-A-induced MMP-7 and
−10 transcriptions and functions in HNC cells.
Aurora-A overexpression is correlated with FLJ10540,
MMP-7 and MMP-10 expression in HNC tissue microarray
To determine the clinical significances of Aurora-A,
FLJ10540, MMP-7, and −10 in HNC patients, we further
examined their expressions in HNC specimens by im-
munohistochemistry in each tissue microarray including
70 cases of HNC samples and 10 cases of normal tissues.
The relative expression levels of these markers were
scored by two independent pathologists. In normal tis-
sues, all of these molecules were expressed weak but de-
tectable. As shown in Figure 7F, Aurora-A expression
was correlated with FLJ10540, MMP-7 and MMP-10 ex-
pressions in HNC tissues. The correlation between each
paired IHC scores of Aurora-A, FLJ10540, MMP-7, and
MMP-10 were analyzed by Spearman’s rank tests. The
result showed that there were positive correlations be-
tween Aurora-A and FLJ10540 (rho =0.776, p < 0.001),
Aurora-A and MMP-7 (rho = 0.825, p < 0.001), Aurora-A
and MMP-10 (rho = 0.728, p < 0.001), FLJ10540 and
MMP-7 (rho = 0.795, p < 0.001), FLJ10540 and MMP-10
(rho = 0.768, p < 0.001) (Additional file 8 Table S1).
Taken together, these results suggest that there is a signifi-
cant positively correlation among Aurora-A, FLJ10540,
MMP-7 and MMP-10 in human HNC.
Discussion
The surgery, radiotherapy and chemotherapy used alone
or in combination, are commonly employed for the
treatment of HNC patients. Recently, molecular targeted
therapies are in development with the goal of selective
approaches to prevent the growth of HNC cells. Aurora-
A and FLJ10540 overexpression has been explored in a
variety of human cancers. However, before this study,
the relationship between these two molecules in HNC
has not been investigated.
In this study, we first demonstrated that both Aurora-
A and FLJ10540 were not only commonly co-amplified,
but also had a similar expression pattern in HNC tumor
tissues and cell lines by using public accessory micro-
array database, Oncomine database, Q-RT-PCR, West-
ern blotting and immunohistochemistry approaches.
Figure 7 (See legend on next page.)
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Figure 7 FLJ10540 not only promotes MMP-7 and −10 expressions through enforced Aurora-A expression, but also has a highly correlation with
Aurora-A, MMP-7 and −10 expressions in human HNC tissues. FLJ10540 induced an increase in MMP-7, and −10 mRNA (A) and protein (B, left
panel) levels in FaDu/FLJ10540 transfectants. (B, right panel) Conditioned media were prepared by incubating FaDu/vehicle and FaDu/FLJ10540
transfectants in serum-free media for 24 hour. MMP-7 and −10 in the samples were analyzed by ELISA. (C and D) The mRNA and protein expression
profiles of MMP-7 and −10 were examined by Q-RT-PCR and Western blotting in SAS/negative control and SAS/siFLJ10540 transfectants.
(E) The MMP-7 and −10 expression levels in conditioned media of vehicle and Aurora-A cotransfected with negative control or siFLJ10540
were assay by ELISA. (F) The FLJ10540, Aurora-A, MMP-7 and MMP-10 expressions in human HNC specimens were investigated by immunohistochemical
staining. Photographs of weak and strong staining for FLJ10540, Aurora-A, MMP-7 and MMP-10 in the sections are shown. Statistical analysis:
*p < 0.05, **p < 0.01, ***p < 0.001.
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that Aurora-A regulates FLJ10540 expression via binding
to the FLJ10540 promoter in HNC cells. In addition, in-
hibition of Aurora-A kinase activity by MLN8237 was
not only significant decrease tumor growth and the
FLJ10540 expression in vitro and in vivo, but also pre-
vented the formation of FLJ10540-PI3K complex in
HNC cells. Aurora-A overexpression in HNC cells elic-
ited the characteristics of aggressive malignancy, such as
proliferation, migration, invasion and centrosome abnor-
mality were dramatic decreased, while endogenous
FLJ10540 was suppressed. However, FLJ10540 overex-
pression significantly reversed the sensitivity of Aurora-
A-depleted cells to cisplatin. Next, increased MMP-7
and MMP-10 activities by Aurora-A or FLJ10540 were
required for increasing cell motility. In addition, Aurora-
A elicited cell motility was dramatic suppressed, while
FLJ10540 and MMP-7/MMP-10 were inhibited simul-
taneously comparing to Aurora-A alone. Finally, the ex-
pression of Aurora-A in HNC tissue microarray was
correlated with elevated FLJ10540, MMP-7, and MMP-
10 expressions. Taken together, we demonstrate a new
molecular mechanism that aberrant Aurora-A expres-
sion in HNC plays a crucial role as positive activator of
MMP-7 and MMP-10 via the function of FLJ10540 to
regulate HNC progression.
It is known that overexpressed Aurora-A in cancer
cells lead to carcinogenesis in multiple types of human
cancers. Previous study has shown that Aurora-A partic-
ipates in PI3K pathway for cancer cell survival [34]. Our
previous data indicated that FLJ10540 could form a
complex with PI3K for promoting tumor growth in HCC
[16]. Recently, we had demonstrated that Aurora-A was
activated in advanced stage of squamous cell carcinoma of
head and neck cancer [12]. In addition, FLJ10540 expres-
sion was correlated with aggressiveness of oral cavity squa-
mous cell carcinoma [19]. Thus, these results suggest that
Aurora-A and FLJ10540 may have functionally linked in
head and neck cancer patients. In this study, we first dem-
onstrated that Aurora-A regulated FLJ10540 expression in
transcriptional and post-transcriptional levels in HNC
cells, suggesting that Aurora-A might regulate PI3K acti-
vation through the FLJ10540 function. As expect, Aurora-
A kinase activity inhibition in HNC cells led to significantdecrease the FLJ10540-PI3K complex formation as well as
FLJ10540 protein levels by using Aurora-A inhibitor of
MLN8237. The decreased FLJ10540-PI3K association was
also observed while Aurora-A was depleted by Aurora-A-
mediated siRNA (data not shown). This is the first time to
unravel how Aurora-A participates in PI3K signaling path-
way in human cancer. These results not only demon-
strated that Aurora-A was an upstream regulator of
FLJ10540, but also revealed cross-talk between Aurora-A
and FLJ10540 in modulating PI3K pathway.
It is noteworthy that down-regulation of Aurora-A or
its targets improves chemosensitivity of human cancers
[35]. However, whether FLJ10540 involved in cisplatin
chemoresistance in Aurora-A depleted cells has not been
reported. In the present study, compared with the corre-
sponding control cells, the viability of Aurora-A depleted
HNC cells was reduced under cisplatin treatment in a
dose-dependent. Moreover, FLJ10540 overexpressed in
Aurora-A-depleted HNC cells or FLJ10540 transfectants
treated with MLN8237 could overcome the chemosensi-
tive characteristic to cisplatin compared to Aurora-A-
depleted cells or vehicle control. Thus, these results
suggest that overexpressed Aurora-A-raised chemoresis-
tant to cisplatin are at least partly, through regulating
FLJ10540 expression.
According to current concept, MMP expression could
maintain tumor microenvironment such as stroma cells,
so inhibited MMP expression would be more effective in a
cancer treatment [33,36]. Several studies reported that
Aurora-A enhances cancer cell metastasis through MMP-
2 expression in human cancers [37,38]. By using Q-RT-
PCR screening approach, we identified that MMP-7 and
MMP-10 expressions, but not MMP-2 were dramatic in-
creased by both Aurora-A and FLJ10540 regulations in
HNC cells. In addition, MMP-7- and MMP-10-elicited
HNC cell motility were regulated by Aurora-A-FLJ10540
expression. This is the first study to unravel that one of
the important upstream regulators of FLJ10540 and
MMP-7/MMP-10 may be regulated by Aurora-A in HNC
cells. Finally, the immunohistochemical analysis showed a
significant correlation that overexpression of Aurora-A
was not only elevated expression of FLJ10540, but also in-
creased MMP-7 and MMP-10 expression in HNC tissues.
However, the molecule mechanisms of FLJ10540 regulated
Figure 8 Schematic presentation for the molecular mechanism by which MMP-7 and MMP-10 expressions is regulated by the Aurora-A/FLJ10540
pathway, resulting in the proliferation, migration, invasion, and chemoresistance of HNC cells.
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tion need to be further elucidated.
In summary, this study highlights the importance of
Aurora-A signaling pathway in the biology of HNC at
clinical tissue, cell line and murine tissue levels. The im-
pact of suppression of Aurora-A pathway is imposed
across all translational related characteristics of HNC
cells such as viability, invasiveness, chemoresistance and
in vivo tumorigenesis.
Conclusions
This study for the first time provides a new insight into
a novel relationship between Aurora-A and FLJ10540
expressions on MMP-7 and MMP-10 activation. This
Aurora-A-FLJ10540-MMP-7/MMP-10 axis is involved
in cancer cell proliferation, migration, invasion and
chemoresistance (Figure 8). Therefore, targeting Aurora-
A-FLJ10540-MMP-7/MMP-10 axis with Aurora-A inhibi-
tor could be an effective therapeutic approach in HNC.
Additional files
Additional file 1: Figure S1. Aurora-A binds to the promoter region of
FLJ10540 in HNC cells. Chromatin immunoprecipitation assay was
performed using Flag or control antibodies (A) or Aurora-A antibody
(B) to pull down DNA fragment on the FLJ10540 promoter from FaDu
and SAS transfected with siAurora-A cells. The FLJ10540 promoter element
was detected by Q-RT-PCR. Statistical analysis: ***p < 0.001.
Additional file 2: Figure S2. Suppression of endogenous FLJ10540
postpones Aurora-A elicited tumor growth and metastasis in vivo. (A) Tumor
growth evaluation of FaDu-vehicle and FaDu-Aurora-A cells transfected withnegative control or siFLJ10540 in xenograft model. Nude mice bearing
subcutaneously established FaDu-vehicle-negative control (n = 6),
FaDu-vehicle-siFLJ10540 (n = 6), FaDu-Aurora-A-negative control (n = 6),
and FaDu-Aurora-A-siFLJ10540 (n = 6) xenograft tumors. Tumor growth
was monitored and was shown as mean volumes ± SD. (B) Using the
same panel, lung metastasis assay and histological analysis from nude
mice. T, metastatic nodule.
Additional file 3: Figure S3. The quantification of gamma-tubulin in
overexpressing Aurora-A stable cells transfected with negative control or
FLJ10540 siRNA. Ratio of gamma-tubulin localized at centrosome was
quantified from 20 images per condition. Statistical analysis: ***p < 0.001.
Additional file 4: Figure S4. The matricellular proteins of MMP-7 and
MMP-10 are increased in Aurora-A stable transfectants. Conditioned
media were prepared by incubating FaDu/vehicle and FaDu/Aurora-A
transfectants, in serum-free media for 24 h. The secrete proteins of
MMP-7 and −10 were analyzed by ELISA. Statistical analysis: ***p < 0.001.
Additional file 5: Figure S5. GM6001 inhibits MMP-7 and −10 mRNA
expressions in Aurora-A stable cells in HNC. The mRNA expression levels
of MMP-7 and −10 were examined by Q-RT-PCR in FaDu/vehicle, and
FaDu/Aurora-A transfectants treated with DMSO or GM6001 in a
dose-dependent manner. Statistical analysis: **p < 0.01, ***p < 0.001.
Additional file 6: Figure S6. GM6001 inhibits FLJ10540-elicited cell
motility in HNC. The migration and invasion assays were performed by
Transwell chambers in FLJ10540 transfectants treated with GM6001
(3 μM). Statistical analysis: ***p < 0.001.
Additional file 7: Figure S7. GM6001 and siFLJ10540 were synergistic
inhibition the Aurora-A-elicited cell motility, growth, and chemoresistance
in HNC. (A) The migration and invasion assays were performed by Transwell
chambers in Aurora-A/FaDu and vehicle cells transfected and/or negative
control or siFLJ10540 following treated with GM6001. (B) The colony
formation was assay in Aurora-A/FaDu transfected with negative control
or siFLJ10540 following treated with GM6001. (C) Using the same panel
B, cells were incubated with cisplatin for 48 h, and their percentage viability
was measured. Statistical analysis: *p < 0.05, **p < 0.01.
Additional file 8: Table S1. The correlation between Aurora-A,
FLJ10540, MMP-7 and MMP-10 expressions in HNC.
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